

Summary of 2020 influenza vaccines – updated 25 May 2020

Influenza.
Don't get it.
Don't give it.

Vaccine brand:	INFLUVAC® TETRA (SAISON 2019/2020)	AFLURIA® QUAD	AFLURIA® QUAD JUNIOR																								
Manufacturer:	<ul style="list-style-type: none"> • Mylan • Phone: 0800 737 271 	<ul style="list-style-type: none"> • Seqirus • Phone: 0800 502 757 																									
Funding status:	<ul style="list-style-type: none"> • Non-funded • Children and adults aged 3–64 years inclusively who are not eligible to receive funded influenza vaccination 	<ul style="list-style-type: none"> • Funded • Eligible children aged 3 years or older and adults • 18 March through 31 December 2020 	<ul style="list-style-type: none"> • Funded • Eligible children aged 6–35 months, • 1 April through 31 December 2020 																								
Presentation:	<ul style="list-style-type: none"> • Pre-filled syringe with needle: 0.5 mL 		<ul style="list-style-type: none"> • Pre-filled syringe with needle: 0.25 mL 																								
Route of administration:	<ul style="list-style-type: none"> • Intramuscular 		<ul style="list-style-type: none"> • Intramuscular 																								
Dosage:	<table border="1"> <thead> <tr> <th>Age</th> <th>Dose</th> <th>Number of doses</th> </tr> </thead> <tbody> <tr> <td>6–35 months</td> <td colspan="2">NOT FOR USE IN THIS AGE GROUP</td> </tr> <tr> <td>3–8 years</td> <td>0.5 mL</td> <td>1 or 2*</td> </tr> <tr> <td>≥ 9 years</td> <td>0.5 mL</td> <td>1</td> </tr> </tbody> </table> <p>* Two doses separated by at least four weeks if influenza vaccine is being used for the first time</p>	Age	Dose	Number of doses	6–35 months	NOT FOR USE IN THIS AGE GROUP		3–8 years	0.5 mL	1 or 2*	≥ 9 years	0.5 mL	1		<table border="1"> <thead> <tr> <th>Age</th> <th>Dose</th> <th>Number of doses</th> </tr> </thead> <tbody> <tr> <td>6–35 months</td> <td>0.25 mL</td> <td>1 or 2*</td> </tr> <tr> <td>3–8 years</td> <td colspan="2">NOT FOR USE IN THESE AGE GROUPS</td> </tr> <tr> <td>≥ 9 years</td> <td colspan="2">NOT FOR USE IN THESE AGE GROUPS</td> </tr> </tbody> </table> <p>* Two doses separated by at least four weeks if influenza vaccine is being used for the first time</p>	Age	Dose	Number of doses	6–35 months	0.25 mL	1 or 2*	3–8 years	NOT FOR USE IN THESE AGE GROUPS		≥ 9 years	NOT FOR USE IN THESE AGE GROUPS	
Age	Dose	Number of doses																									
6–35 months	NOT FOR USE IN THIS AGE GROUP																										
3–8 years	0.5 mL	1 or 2*																									
≥ 9 years	0.5 mL	1																									
Age	Dose	Number of doses																									
6–35 months	0.25 mL	1 or 2*																									
3–8 years	NOT FOR USE IN THESE AGE GROUPS																										
≥ 9 years	NOT FOR USE IN THESE AGE GROUPS																										
Components of special note:																											
– Antibiotics:	<ul style="list-style-type: none"> • Gentamicin 	<ul style="list-style-type: none"> • Neomycin and polymixin B 																									
– Latex:	<ul style="list-style-type: none"> • Cannot be considered latex-free 	<ul style="list-style-type: none"> • Latex-free 																									
– Ovalbumin (egg protein):	<ul style="list-style-type: none"> • Each 0.5 mL dose contains less than 1 microgram of ovalbumin 	<ul style="list-style-type: none"> • Each 0.5 mL dose contains less than 1 microgram of ovalbumin 																									
Vaccine expiry date:	<ul style="list-style-type: none"> • 31 August 2020[#] [#]Extension of the vaccine expiry date beyond the date printed on the packaging (30 June 2020) was based on technical advice 	<ul style="list-style-type: none"> • 28 February 2021 																									
Influenza strains:	<ul style="list-style-type: none"> • A/Brisbane/02/2018 (H1N1) pdm09-like virus • A/Kansas/14/2017 (H3N2)-like virus • B/Colorado/06/2017-like virus (close relative of B/Washington strain) • B/Phuket/3073/2013-like virus 	<ul style="list-style-type: none"> • A/Brisbane/02/2018 (H1N1) pdm09-like virus • A/South Australia/34/2019 (H3N2)-like virus • B/Washington/02/2019-like virus • B/Phuket/3073/2013-like virus 																									
Precaution:	<ul style="list-style-type: none"> • Influenza vaccination may be contraindicated or need to be delayed for people receiving the following cancer treatments, atezolizumab (TECENTRIQ®), ipilimumab (YERVOY®), nivolumab (OPDIVO®) and pembrolizumab (KEYTRUDA®), for more information, please refer to page 16 of the Flu Kit Booklet 2020 																										
Storage:	<ul style="list-style-type: none"> • Vaccines must be stored, protected from light, at +2°C to +8°C. DO NOT FREEZE • Temperature-monitored chilly bins must be used if vaccines are temporarily stored outside the vaccine refrigerator or being transported • Quarantine vaccines stored outside the required temperature range and contact your Immunisation/Cold Chain Coordinator 																										
Order from:	<ul style="list-style-type: none"> • Healthcare Logistics (HCL) • Phone: 0508 425 358 • Fax: 0508 408 358 • hcl.co.nz 																										

INFLUVAC® TETRA (SAISON 2019/2020), AFLURIA® QUAD and AFLURIA® QUAD JUNIOR are prescription only medicines. Please refer to the Medsafe data sheets for further details. [medsafe.govt.nz](https://www.medsafe.govt.nz) and [influenza.org.nz](https://www.influenza.org.nz)



[influenza.org.nz](https://www.influenza.org.nz)
0800 IMMUNE
(0800 466 863)
[immune.org.nz](https://www.immune.org.nz)